Global /United States /Healthcare /Biotechnology /TTNP

Titan Pharmaceuticals, Inc.

TTNP

• NASDAQ: TTNP • Delayed

4.61USD -3.8%

As of 14 June 2026, Titan Pharmaceuticals, Inc. has a market cap of $6.13M USD, ranking #43615 globally and #5577 in the United States. It ranks #3866 in the Healthcare sector, and #760 in the Biotechnology industry.

Global Rank

43615

Country Rank

5577

Sector Rank

3866

Industry Rank

760

Key Stats

Market Cap

$6.13MUSD

Enterprise Value

$3.57MUSD

EBITDA (TTM)

-$2.61MUSD

Net Income (TTM)

-$2.81MUSD

PB Ratio

2.3

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Weei Chay open_in_new

Employees

Founded

1991

IPO

18 Jan 1996

Website

titanpharm.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.8%	7.6%	16%	9.8%	31%	41%	-13%	-79%	-95%

News

TTNP Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	TTNP Titan Pharmaceuticals Inc ISIN: US8883147055 Shares Out.: Shares Outstanding: 1.33M¹ Shares Float: 514.189K² TV: TradingView: NASDAQ: TTNP SA: Stock Analysis: NASDAQ: TTNP YF: Yahoo Finance: TTNP GF: Google Finance: NASDAQ: TTNP NQ: NASDAQ: TTNP BA: Barron's: TTNP MS: Morningstar: XNAS: TTNP	4.61 USD	TV: TradingView: NASDAQ: TTNP SA: Stock Analysis: NASDAQ: TTNP YF: Yahoo Finance: TTNP GF: Google Finance: NASDAQ: TTNP NQ: NASDAQ: TTNP BA: Barron's: TTNP MS: Morningstar: XNAS: TTNP

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 3M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 3M%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 450K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 429K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 408K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 296K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 780K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 731K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 691K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 690K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 458K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 419K%	-	Germany

chevron_leftBack